Treatment of tuberculosis : (Record no. 2218)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02597nam a22002057a 4500 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | OSt |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20191226214828.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 111018t xxu||||| |||| 00| 0 eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 9789241547833 |
060 ## - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
Classification number | WF 360 T 2010 |
245 00 - TITLE STATEMENT | |
Title | Treatment of tuberculosis : |
Remainder of title | guidelines. |
250 ## - EDITION STATEMENT | |
Edition statement | 4th ed. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Place of publication, distribution, etc. | Geneva : |
Name of publisher, distributor, etc. | World Health Organization, |
Date of publication, distribution, etc. | 2010. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | x, 147 p. : |
Other physical details | ill. ; |
Dimensions | 24 cm. |
504 ## - BIBLIOGRAPHY, ETC. NOTE | |
Bibliography, etc. note | Includes bibliographical references. |
520 ## - SUMMARY, ETC. | |
Summary, etc. | The World Health Organization's Stop TB Department has prepared this fourth edition of Treatment of Tuberculosis: Guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition.<br/><br/>First, the recommendation to discontinue the regimen based on just 2 months of rifampicin (2HRZE/6HE) and change to the regimen based on a full 6 months of rifampicin (2HRZE/4HR) will reduce the number of relapses and failures. This will alleviate patient suffering resulting from a second episode of tuberculosis (TB) and conserve patient and programme resources.<br/><br/>Second, this fourth edition confirms prior WHO recommendations for drug susceptibility testing (DST) at the start of therapy for all previously treated patients. Finding and treating multidrug-resistant TB (MDR-TB) in previously treated patients will help to improve the very poor outcomes in these patients. New recommendations for the prompt detection and appropriate treatment of (MDR-TB) cases will also improve access to life-saving care.<br/><br/>Third, detecting MDR-TB will require expansion of DST capacity within the context of country-specific, comprehensive plans for laboratory strengthening. This fourth edition provides guidance for treatment approaches in the light of advances in laboratory technology and the country's progress in building laboratory capacity.<br/><br/>Fourth, diagnosing MDR-TB cases among previously treated patients and providing effective treatment will greatly help in halting the spread of MDR-TB. This edition also addresses the prevention of acquired MDR-TB, especially among new TB patients who already have isoniazid-resistant Mycobacterium tuberculosis when they start treatment.<br/><br/>Finally, this edition strongly reaffirms prior recommendations for supervised treatment, as well as the use of fixed-dose combinations of anti-TB drugs and patient kits as further measures for preventing the acquisition of drug resistance. |
650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antitubercular Agents |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Source of classification or shelving scheme | National Library of Medicine Classification |
Koha item type | WHO Publications |
Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Date last checked out | Price effective from | Koha item type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
National Library of Medicine Classification | FNPH LIBRARY | FNPH LIBRARY | 18/10/2011 | 2 | WF 360 T 2010 | 03344 | 23/05/2016 | 06/05/2016 | 18/10/2011 | WHO Publications |